Cover Image
市場調查報告書

Sevion Therapeutics, Inc.的產品平台分析

Sevion Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321986
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Sevion Therapeutics, Inc.的產品平台分析 Sevion Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 24 Pages
簡介

Sevion Therapeutics, Inc.是總公司設立於美國的製藥企業,利用真核起始因子5A(eIF5A)技術,提供控制細胞生死 的產品及技術。對像領域有癌症及發炎疾病。

本報告提供Sevion Therapeutics, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Sevion Therapeutics, Inc. 的基本資料

  • Sevion Therapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Sevion Therapeutics, Inc. :R&D概要

  • 主要的治療範圍

Sevion Therapeutics, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Sevion Therapeutics, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Sevion Therapeutics, Inc. :藥物簡介

  • SNS-01T
  • insulin human
  • SVN-001
  • SVN-002
  • Monoclonal Antibodies to Modulate GPCR for Cancer
  • Monoclonal Antibody to Modulate Ion Channel for Pain

Sevion Therapeutics, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sevion Therapeutics, Inc. :最新的開發平台資訊

Sevion Therapeutics, Inc. :中止開發的計劃

Sevion Therapeutics, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07902CDB

Summary

Global Markets Direct's, 'Sevion Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Sevion Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sevion Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sevion Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sevion Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sevion Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Sevion Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sevion Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sevion Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sevion Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sevion Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sevion Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sevion Therapeutics, Inc. Snapshot
    • Sevion Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Sevion Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sevion Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Sevion Therapeutics, Inc. - Pipeline Products Glance
    • Sevion Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sevion Therapeutics, Inc. - Drug Profiles
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVN-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVN-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Modulate GPCR for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Modulate Ion Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sevion Therapeutics, Inc. - Pipeline Analysis
  • Sevion Therapeutics, Inc. - Pipeline Products by Target
  • Sevion Therapeutics, Inc. - Pipeline Products by Molecule Type
  • Sevion Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Sevion Therapeutics, Inc. - Dormant Projects
  • Sevion Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • SNS-01T
  • Sevion Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sevion Therapeutics, Inc., Key Information
  • Sevion Therapeutics, Inc., Key Facts
  • Sevion Therapeutics, Inc. - Pipeline by Indication, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sevion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sevion Therapeutics, Inc. - Preclinical, 2015
  • Sevion Therapeutics, Inc. - Discovery, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Target, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Sevion Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Sevion Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Sevion Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Sevion Therapeutics, Inc., Subsidiaries

List of Figures

  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sevion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Sevion Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top